Disclosure of trading in own shares occurred from October 28 to October 31, 2025 Saint-Cloud, November 4, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from October 28 to October 31, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction da ...

Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%.• EBIT1,2 was DKK 7,670 million, a 5% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.• Adjusted3 net profit before special items was DKK 5,148 m ...

2024/25Full year financial results 1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%.• Growth in Ostomy Care was broad based with good contribution from recent product launches and led by Europe a ...

核心观点 - 国际石油公司2025年第三季度运营表现强劲 平均净产量高于指导范围 Blackrod项目第一阶段开发进度超前 [1][2][3] - 公司通过债券再融资和股票回购优化资本结构 并计划延续股东回报策略 [4][24][26] - 尽管面临油价波动等宏观挑战 公司维持2025年全年产量指引 并对中长期行业基本面持建设性观点 [6][8][9] 运营业绩 - 2025年第三季度平均净产量约为每日45,900桶油当量 超出指导范围 其中重质原油占53% 轻质和中质原油占14% 天然气占33% [2][7] - Onion Lake Thermal资产按计划完成生产加密井的投产 [7] - 第三季度每桶油当量运营成本为179美元 略低于指导值 [7][15] - 2025年全年平均净产量指导范围维持在每日43,000至45,000桶油当量 [6][14] Blackrod项目进展 - Blackrod项目第一阶段开发进度超前 首次注汽预计在2025年底 首次产油预计在2026年第三季度 比原计划提前一个季度 [1][3] - 项目中心处理设施建设接近完成 逐步调试工作进展顺利 [3][21] - 由于启动时间提前 最后一个井场的钻探已加速至2025年第四季度进行 [3][22] - 项目增长资本预算保持为850百万美元 截至第三季度末已发生支出785百万美元 占首油前总预算的92% [3][20] 财务表现 - 2025年第三季度营业收入为172,297千美元 九个月累计营业收入为509,681千美元 [8] - 第三季度运营现金流为66,102千美元 符合指引 九个月累计运营现金流为195,765千美元 [7][8][15] - 第三季度资本和弃置支出为82,000千美元 符合指引 [7][16] - 第三季度自由现金流为-23,083千美元 若扣除Blackrod资本支出则为36,000千美元 [7][17] - 第三季度净利润为3,802千美元 九个月累计净利润为33,883千美元 [8] - 截至2025年9月30日 总现金为45,000千美元 净债务为435,000千美元 [7][18] 资本管理与股东回报 - 公司在第三季度成功完成2024/2025年度正常程序发行人回购 期间共回购并注销约750万股普通股 相当于2024年12月初流通股的62% [4][7][24] - 公司计划在2025年12月寻求多伦多证券交易所批准 续期下一轮NCIB 预计可进一步回购约650万股普通股 约占当前流通股的58% [7][26] - 公司于2025年10月成功完成450百万美元无担保债券的再融资 新债券期限至2030年10月 票面利率为75% [4][19] 市场环境与对冲 - 2025年第三季度布伦特原油平均价格约为每桶69美元 相对稳定 [8] - 公司对约50%的2025年预测石油产量进行了对冲 布伦特和WTI价格分别约为每桶76美元和71美元 [10] - 第三季度WTI与WCS价差平均低于每桶11美元 公司已对约50%的2025年预测加拿大石油产量进行了价差对冲 价格为每桶14美元 [11] - 公司对约50%的2025年10月底前净多头天然气风险敞口进行了对冲 价格为每千立方英尺24加元 [13] 2025年全年指引更新 - 全年运营成本指导范围维持在每桶油当量180至190美元 [12][15] - 全年运营现金流指导范围收窄至245至255百万美元 假设2025年剩余时间布伦特油价为每桶55至65美元 [12][15] - 全年资本和弃置支出指导从320百万美元修订为340百万美元 主要由于Blackrod项目钻探活动提前 [12][16] - 全年自由现金流指导修订为-170至-160百万美元 假设2025年剩余时间布伦特油价为每桶55至65美元 [12][17]

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the "Retail Offering"). Radforsk Investeringsstiftelse ("Radforsk") holds 2,469,693 sha ...

会议与数据展示 - 诺华将在2025年美国肾脏病学会肾脏周和美国心脏协会科学会议上展示来自其心血管、肾脏和代谢疾病产品组合的33篇摘要数据[1] - 展示数据涵盖已上市和在研疗法，体现了公司在从最罕见至最普遍的心血管、肾脏和代谢疾病领域的长期投入[2] 核心产品管线亮点 - Fabhalta（iptacopan）将公布针对IgA肾病东亚患者的3期APPLAUSE-IgAN试验中期结果，以及针对C3肾小球病的3期APPEAR-C3G试验中期结果和长达39个月的扩展研究数据[2] - Vanrafia（atrasentan）将公布针对IgA肾病的3期ALIGN试验东亚患者亚组中期分析数据[2] - Zigakibart将公布其1/2期试验中针对IgA肾病患者的长期肾功能稳定性的亚组分析数据[2][5] - Farabursen将公布其可增加常染色体显性多囊肾病患者尿多囊蛋白-1和-2并降低身高调整总肾脏体积增长的数据[5] 心血管疾病领域数据 - Leqvio（inclisiran）将公布VICTORION-INCEPTION研究数据，支持在急性冠脉综合征后早期加用该药作为降脂管理策略，其基于inclisiran的治疗策略与标准治疗相比对生活质量和肌肉相关疼痛影响的探索性结果也将公布[5] - 脂蛋白(a)数据将强调其在早发性动脉粥样硬化性心血管疾病患者中作为独立危险因素的重要性，以及针对脂蛋白(a)的疗法（如pelacarsen）的潜在益处[5] - Pacibekitug将公布其2期TRANQUILITY试验中针对高敏C反应蛋白升高和慢性肾病患者的90天分析数据[5] 公司战略与管线拓展 - 公司致力于通过前沿科学和科技解决心血管、肾脏和代谢这些相互关联的疾病，目标是实现无可预防的心血管疾病死亡[7] - 诺华近期收购了Tourmaline Bio，获得了处于三期准备阶段的抗IL-6单抗pacibekitug的全球权利，以补充其心血管管线[11] - 公司拥有超过40年在心血管和肾脏疾病领域的历史，并通过其强大的产品组合和不断增长的研发管线继续推进[7]

In the third quarter of 2025, EfTEN United Property Fund earned a net profit of 426 thousand euros (Q3 2024: 134 thousand euros). The fund's income increased from 176 thousand euros to 468 thousand euros year-on-year, while expenses remained unchanged. The fund's assets amounted to 28,167 thousand euros as of 30.09.2025 (31.12.2024: 27,478 thousand euros). EfTEN United Property Fund's investments performed as expected in the third quarter of 2025. In larger commercial real estate premices, where the fund ha ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in Europe exceeded the threshold triggering a USD 30 million sales milestone payment. David Veitch, Basil ...

SHANGHAI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The 2025 Tour of Chongming Island, part of the UCI Women's WorldTour, has kicked off on Shanghai's world-class ecological island, bringing together elite cyclists, amateur riders, and fans for a three-day celebration of sport, sustainability, and local culture. A Media Snippet accompanying this announcement is available by clicking on this link. Co-hosted by the Union Cycliste Internationale (UCI), China's General Administration of Sport, and the Shanghai Municip ...

Kinepolis signs agreement to acquire the operations of US movie theatre chain Emagine Entertainment Regulatory release - Inside information 4 November 2025, 7:00 AM CET Kinepolis (Euronext: KIN) has reached an agreement to acquire the operations of the US movie theatre chain Emagine Entertainment. Kinepolis expects to complete the acquisition by the end of the year. As a result of this agreement, Kinepolis will add 14 cinemas to its portfolio, representing 177 screens and 18,000 seats, located in Michigan ...